Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Phase 2
Completed
- Conditions
- AnemiaNon-Myeloid MalignanciesCancer
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Registration Number
- NCT00111462
Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT00111098
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Phase 3
Completed
- Conditions
- CancerNon-Myeloid Malignancies
- Interventions
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 718
- Registration Number
- NCT00111137
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Phase 3
Completed
- Conditions
- AnemiaNon-Myeloid Malignancies
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT00110955
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT00096915
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Phase 2
Completed
- Conditions
- Anemia
- First Posted Date
- 2004-11-03
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 220
- Registration Number
- NCT00095277
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2004-11-03
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 209
- Registration Number
- NCT00095264
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Kidney DiseaseChronic Kidney Disease
- Interventions
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1100
- Registration Number
- NCT00093977
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
Phase 3
Completed
- Conditions
- Kidney DiseaseDiabetes MellitusAnemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-09-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4038
- Registration Number
- NCT00093015
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1000
- Registration Number
- NCT00091858
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath